Back to the Top
Dear All,
"Multi-dose Steady State studies eliminate the need for long washout
period"
I would be thankful, if you kindly clarify the scientific reason
behind the above statement.
Regards,
Habeeb Ibrahim
Back to the Top
The following message was posted to: PharmPK
Dear Habeeb!
> "Multi-dose Steady State studies eliminate the need for long washout
> period"
Where does your quote come from?
Maybe this thread helps:
http://forum.bebac.at/mix_entry.php?id=477
Best regards,
Helmut
--
Ing. Helmut Schuetz
BEBAC - Consultancy Services for
Bioequivalence and Bioavailability Studies
Neubaugasse 36/11
1070 Vienna, Austria
tel/fax +43 1 2311746
e-mail helmut.schuetz.-a-.bebac.at
web http://bebac.at
forum http://forum.bebac.at
Back to the Top
Folks: Why wouldn't it be as follows?
The reason for the long washout would be to avoid a carryover effect
from the first to the second dose, ie: a residual amount of dose 1.
If the washout were incomplete what would happen is that dose 2
bioavailability would seem to be too high. If that happened what
would be the problem? In the clinical situation, ie: a repeated dose
schedule, the drug might accumulate more than expected....... so
measure it. A Pk profile in the repeat dose steady state will tell
you if more is being absorbed than expected.
Isn't that QED?
Andrew Sutton
Andrew Sutton, MBBS, MD(London), FFA
Consultant in Clinical Pharmacology
URL: www.gcpl.co.uk
Back to the Top
Dear Helmut, Amit and Andrew,
Thanks for the kind response. I have taken the quote from 'Basic
Pharmacokinetics by Rasma Chereson' Chapter 8 - Bioavailability,
Bioequivalence and Drug Selection - Table 8-8 - Pg 14 of 111
http://pharmacyonline.creighton.edu/pha443/pdf/pkin08.pdf
Regards,
Habeeb Ibrahim
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Washout in Steady state studies" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)